Articles

Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer. Read More ›

No significant differences in PFS were found between abemaciclib, palbociclib, and ribociclib in a real-world setting. Read More ›

In vitro study finds combination approaches with alpelisib in triple-negative breast cancer harboring PIK3CA mutations provide synergistic effect. Read More ›

Clinical trial assessing the additive benefit of alpelisib to fulvestrant in treatment-refractory HR-positive/HER2-negative ABC currently enrolling patients. Read More ›

Results from the SOLAR-1 study demonstrate that only PIK3CA mutations can predict sensitivity to alpelisib in patients with HR-positive/HER2-negative breast cancer. Read More ›

Findings from Cohort A of the BYLieve study suggest that treatment of HR-positive/HER2-negative breast cancer with PIK3CA mutation drivers with alpelisib plus fulvestrant may lead to long-term disease control. Read More ›

Clinical trial assessing alpelisib plus tucatinib in HER2-positive mBC with PIK3CA mutations is currently enrolling patients. Read More ›

Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer. Read More ›

Post-progression targeted therapy after ribociclib found to result in increased duration of therapy. Read More ›

Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date. Read More ›